Sources | Names Used |
---|---|
CTRPv2 | erlotinib:PLX-4032 (2:1 mol/mol) |
PharmacoGx | erlotinib:PLX-4032 (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | POLR3A | CTRPv2 | pan-cancer | AAC | -0.17 | 1e-05 |
mRNA | VCX3A | CTRPv2 | pan-cancer | AAC | 0.16 | 1e-05 |
mRNA | SCEL | CTRPv2 | pan-cancer | AAC | 0.17 | 1e-05 |
mRNA | TEX37 | CTRPv2 | pan-cancer | AAC | 0.16 | 1e-05 |
mRNA | C16orf74 | CTRPv2 | pan-cancer | AAC | 0.18 | 1e-05 |
mRNA | DXO | CTRPv2 | pan-cancer | AAC | -0.17 | 1e-05 |
mRNA | BAIAP2 | CTRPv2 | pan-cancer | AAC | 0.18 | 2e-05 |
mRNA | IP6K1 | CTRPv2 | pan-cancer | AAC | -0.17 | 2e-05 |
mRNA | VCX2 | CTRPv2 | pan-cancer | AAC | 0.16 | 2e-05 |
mRNA | DDR1 | CTRPv2 | pan-cancer | AAC | 0.2 | 2e-05 |